| References: |
Potent EP2 receptor antagonist (IC50 = 16 nM for human EP2 receptors). Displays over 2000-fold selectivity for EP2 receptors over EP1, EP3, EP4, DP1 amd CRTH2 receptors; exhibits <30% binding at a diverse panel of GPCRs and ion channels at a concentration of 10 μM. Inhibits PGE2-induced increases in intracellular cAMP; reverses PGE2-invoked relaxation of mouse trachea (IC50 = 2.7 nM). For the detailed information of PF-04418948, the solubility of PF-04418948 in water, the solubility of PF-04418948 in DMSO, the solubility of PF-04418948 in PBS buffer, the animal experiment (test) of PF-04418948, the cell expriment (test) of PF-04418948, the in vivo, in vitro and clinical trial test of PF-04418948, the EC50, IC50,and affinity,of PF-04418948, For the detailed information of PF-04418948, the solubility of PF-04418948 in water, the solubility of PF-04418948 in DMSO, the solubility of PF-04418948 in PBS buffer, the animal experiment (test) of PF-04418948, the cell expriment (test) of PF-04418948, the in vivo, in vitro and clinical trial test of PF-04418948, the EC50, IC50,and affinity,of PF-04418948, Please contact DC Chemicals. |
